Commenting on the development , Pfizer Chairman and CEO Ian Read said : " The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research , discover and deliver more medicines and therapies to more people around the world . " Through this combination , Pfizer will have greater financial flexibility that will facilitate " our continued discovery and development of new innovative medicines for patients , direct return of capital to shareholders , and continued investment in the United States , while also enabling our pursuit of business development opportunities on a more competitive footing within the industry , " he added .
